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Abstract
Background: To investigate the combined use of intravoxel incoherent motion (IVIM) diffusion-weighted (DW) and
blood oxygen level dependent (BOLD) magnetic resonance imaging (MRI) to assess rat renal function using a 1.5T
clinical platform.
Methods: Multiple b-value DW and BOLD MR images were acquired from adult rats using a parallel clinical coil
arrangement, enabling quantitation of the apparent diffusion coefficient (ADC), IVIM-derived diffusion coefficient (D),
pseudodiffusion coefficient (D*) and perfusion fraction (f), and the transverse relaxation time T2*, for whole kidney, renal
cortex, and medulla. Following the acquisition of two baseline datasets to assess measurement repeatability, images
were acquired following i.v. administration of hydralazine, furosemide, or angiotensin II for up to 40 min.
Results: Excellent repeatability (CoV <10 %) was observed for ADC, D, f and T2* measured over the whole
kidney. Hydralazine induced a marked and significant (p < 0.05) reduction in whole kidney ADC, D, and T2*, and
a significant (p < 0.05) increase in D* and f. Furosemide significantly (p < 0.05) increased whole kidney ADC, D,
and T2*. A more variable response to angiotensin II was determined, with a significant (p < 0.05) increase in
medulla D* and significant (p < 0.05) reduction in whole kidney T2* established.
Conclusions: Multiparametric MRI, incorporating quantitation of IVIM DWI and BOLD biomarkers and
performed on a clinical platform, can be used to monitor the acute effects of vascular and tubular modulating
drugs on rat kidney function in vivo. Clinical adoption of such functional imaging biomarkers can potentially
inform on treatment effects in patients with renal dysfunction.
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Background
Decreased renal perfusion and medullary oxygenation are
considered predisposing factors to the onset of acute kid-
ney injury [1]. Furthermore, renal medullary oxygenation
has been implicated in hypertension and diabetic ne-
phropathy [2, 3]. Non-invasive imaging techniques such
as magnetic resonance imaging (MRI) are being actively
evaluated pre-clinically to advance the understanding of
renal microcirculation and pathophysiology in vivo, with a
strong emphasis on establishing their robustness for clin-
ical translation [4].
MRI is an important tool for clinical disease assessment
and treatment response. In addition to exquisite soft tissue
contrast and anatomic detail, advanced functional MRI
techniques, such as diffusion-weighted imaging (DWI)
and blood oxygenation level-dependent (BOLD) MRI now
provide a means of defining quantitative biomarkers to in-
form on biologically relevant structure-function relation-
ships in tissues, enabling an understanding of their
behaviour and spatial distribution [5].
In nephrology, application of a monoexponential model
to DW MR images of increasing diffusion-weighting yields
the apparent diffusion coefficient (ADC), shown to de-
crease as a consequence of acute tubular necrosis, renal
artery stenosis, and acute and chronic renal failure, as well
as post-transplant kidney rejection [6–8]. The biexponen-
tial intravoxel incoherent motion (IVIM) model reports
two distinct diffusion constants as fractional components;
the pseudodiffusion constant D*, of fractional volume f,
associated with a faster incoherent flow component, and
D which reflects random tissue water diffusion [9]. Highly
vascular tissues such as the kidney show non-
monoexponential signal decay with increasing diffusion
weighting (b-value) [10, 11], thought to reflect a rapidly
decaying signal component visible at lower b-values. The
physiological contribution towards this fast diffusion com-
ponent is however complex because of the presence of a
tubular flow fraction, which may exhibit similar diffusion
characteristics to the vascular contribution. Using IVIM
DWI may improve the understanding of the contribution
of renal tubular flow towards the diffusion signal [12].
BOLD MRI has been extensively used both pre-
clinically and clinically to assess renal medullary oxygen-
ation, using deoxyhaemoglobin as an endogenous con-
trast agent. Deoxyhaemoglobin is paramagnetic and
creates magnetic susceptibility perturbations around
blood vessels, decreasing the MRI transverse relaxation
time T2*. As the oxygenation state of haemoglobin is re-
lated to the arterial blood paO2, which is in equilibrium
with tissue pO2, changes in renal T2* are used to infer
alterations in renal pO2 [13].
Multiparametric MRI strategies, enabling the investi-
gation of several imaging biomarkers in the same im-
aging session, are being increasingly exploited to provide
additional mechanistic insight. The combination of
IVIM DWI with BOLD imaging has the potential to illu-
minate the relative sensitivity of the biexponential DWI
signal to vascular versus tubular flow, by observing and
correlating the changes in IVIM parameters with T2*
[14, 15]. In this study, the repeatability of, and the effects
of established pharmacological/physiological interven-
tions known to modulate renal vascular flow and/or
renal tubular excretion on, IVIM DWI and BOLD MRI
biomarkers were investigated in the rat kidney in vivo.
This multiparametric imaging strategy was applied on a
clinical 1.5T MRI platform, using standard clinical
hardware, and used the known actions of hydralazine,
furosemide, and angiotensin II to probe the spatial rela-
tionship between blood oxygenation, blood flow, vascu-
lar fraction, and tubular flow within the kidney.
Methods
Animal preparation
This study was performed in accordance with the
local ethical review panel, the UK Home Office Ani-
mals (Scientific Procedures) Act 1986, the United King-
dom National Cancer Research Institute guidelines for the
welfare of animals in cancer research and the ARRIVE
(animal research: reporting in vivo experiments) guide-
lines [16, 17] (see Additional file 1 for ARRIVE checklist).
Female Sprague-Dawley rats (n = 4 total, three randomised
to each imaging session, 250–300 g, Charles River, Mar-
gate, UK) were anaesthetised with a 4 ml/kg intraperito-
neal injection of fentanyl citrate (0.315 mg/ml) plus
fluanisone (10 mg/ml (Hypnorm; Janssen Pharmaceutical
Ltd. High Wycombe, UK)), midazolam (5 mg/ml (Hypno-
vel; Roche)), and water (1:1:2). A lateral tail vein was can-
nulated with a heparinised 27G butterfly catheter
(Venisystems, Hospira, Royal Leamington Spa, UK) to
enable the remote administration of drugs.
MRI acquisition
MRI was performed on a MAGNETOM Avanto 1.5T,
60 cm horizontal-bore clinical scanner (Siemens Health-
care, Erlangen, Germany). The rat was secured supine
along the magnet axis centred on top of a small-loop
temporomandibular joint (TMJ) coil, and placed within
the multi-element head receiver coil. Animals were sup-
ported using an insulating vacuum beanbag; use of the
beanbag was sufficient to retain the animal’s body heat
through the imaging session, as well as to prevent exces-
sive movement. Elements of the head coil array were
used in parallel with the small-loop coil during all acqui-
sitions. Scans were performed in the coronal plane, with
multiple imaging sections covering both kidneys. Mor-
phological images were obtained for anatomical localisa-
tion, with multi-slice fast spin-echo sequence, repetition
time (TR) = 800 ms, echo time (TE) = 9.6 ms, voxel size
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0.5 mm2 in-plane, 1 mm thick slice, matrix 256 × 149,
scan time 4 min 30 s.
For DWI studies, images were acquired in free-
breathing using a 2D EPI sequence with spectral attenu-
ated inversion recovery (SPAIR) fat suppression, TR =
2.1 s and TE = 71 ms, with 9 b-values (0, 20, 40, 60, 80,
100, 200, 400, 800 s/mm2 trace-weighted), isotropic
voxel size 1.5 mm3, matrix 72 × 72, parallel imaging fac-
tor of 2 and 18 signal averages (acquisition time
16 min). The imaging sequence mirrors the b-values
used for clinical diffusion-weighted imaging in patients.
DW images were thus acquired prior to and 40 min after
administration of drug, or with 40 min spacing for re-
peatability data; based on extant literature it was pre-
dicted that this time window would be sufficient to
capture the long action of administered agents [18].
BOLD imaging was performed using a multiple gradi-
ent echo sequence, with TR = 300 ms, TE = 5, 10, 20, 30,
and 40 ms, fat suppression, parallel imaging factor 2,
voxel size 0.6 × 0.6 mm in-plane and 5 mm slice thick-
ness. A 128 × 128 matrix was acquired and interpolated
to 256 × 256. The flip angle was 25°, with 12 long-term
signal averages, giving an acquisition time of 4 min 30 s.
BOLD data were acquired at baseline, and repeated three
times (scan time for all BOLD measurements 18 min)
immediately following administration of drug.
For each rat, imaging was performed twice in the same
session without any drug administration to determine
measurement repeatability and coefficients of variation
(CoV), and before and after administration of each drug.
The animals were allowed to fully recover before any
subsequent imaging session. Rats were administered
with either hydralazine (5 mg/kg, Sigma-Aldrich, Poole,
UK), furosemide (5 mg/kg, Sigma-Aldrich), both given
as a bolus injection, or angiotensin II (Sigma-Aldrich),
with a half-life of 16 ± 1 s [19], infused at 0.5 μg/min/kg
using a power injector. The known acute effects of these
drugs are vasodilation, diuresis, and vasoconstriction, re-
spectively, and thus expected to induce MRI signal
changes in renal perfusion/tubular flow over the imaging
timecourse.
MRI data analysis
DW images were reviewed and analysed by an MR sci-
entist with 4 years experience in conducting pre-clinical
MR studies. DW-MRI and BOLD images were processed
using proprietary software (ADEPT, The Institute of
Cancer Research, UK). DWI ROIs were drawn on the
central slice of each kidney through the equator plane
on the calculated S0 image, using anatomic T2-weighted
and b = 800 s/mm2 images for reference, around the en-
tire renal outline (91 ± 12 voxels) of both kidneys, and
within regions of the cortex and medulla (28 ± 7 voxels),
defined as the single voxel outline of the kidney and the
region inside, respectively (see Fig. 1 for example ROIs).
For each analysis, fitting for perfusion-insensitive ADC
(×10−5 mm2s−1) was performed using images for b =
200 s/mm2 and above, with a single-exponential model
and a Levenberg-Marquardt algorithm. In tissues where
the monoexponential ADC model is known to be a poor
model, excluding the b-values known to be most sensi-
tive to perfusion minimizes the dependence of resultant
ADC on the exact choice of b-values used [20]. All b-
value images were used for IVIM curve fitting; initial par-
ameter estimates were obtained by fitting a monoexpo-
nential model at b > 200 s/mm2 to give an estimate of D,
and projecting back to b = 0 to provide an initial estimate
of the perfusion fraction f. Following this, an adaptation of
Bayesian approaches [21, 22] was applied to all b-value
data to derive final estimates of D (×10−5 mm2 s−1), f (%),
and the pseudodiffusion coefficient D* (×10−2 mm2 s−1).
The product estimate fD* (×10−4 mm2s−1), associated with
flow, was also calculated; the adapted Bayesian approach
assumed Gaussian data errors and uniform prior distribu-
tions for all unknown parameters.
For BOLD images, partial volume effects from slice
thickness precluded accurate separation of the renal cor-
tex and medulla, hence ROIs were drawn around the cen-
tral slice of each kidney in the equatorial plane (516 ±
58 voxels). Single-exponential fitting with the Levenberg-
Marquardt algorithm yielded estimates for T2*; sufficient
signal to noise (SNR >20) was recorded at all echo times,
and noise was not included in the model.
Fig. 1 Representative MRI images. Typical images from a) T2-weighted anatomical scan, with corresponding b) ADC map and c) T2* map from a
matched slice, including example ROIs to indicate the selections for analysis of renal cortex and medulla
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For all analyses, the median values for each ROI were
reported, reducing effects from voxels where fitting did
not converge. In cases where the slice positioning or sig-
nal precluded confident drawing of the ROI, the kidney
was excluded from analysis (n = 1, furosemide).
For statistical comparison, significance of results was
assessed using non-parametric tests at 5 % using a
Wilcoxon paired rank sum for DWI measurements, with
a one-way ANOVA for the repeated BOLD measure-
ments. The Pearson correlation statistic was calculated for
values of the related diffusion parameters ADC and D.
Results
The use of parallel clinical coils on the 1.5T platform
provided sufficient signal for functional MRI of the rat
kidney. Representative anatomical T2-weighted images,
and associated parametric ADC and T2* maps calculated
from the same rat, with the renal cortex and medulla de-
lineated in ADC map and whole kidney on T2*, are
shown in Fig. 1.
DW MRI model comparison
In all cases, non-monoexponential behaviour was evi-
dent in the kidneys from plots of signal intensity against
b-value. The baseline signal intensity curve against b-
value for a representative renal voxel is shown in Fig. 2.
Non-monoexponential decay was evident, with the over-
laid fitted curves for monoexponential ADC and biexpo-
nential IVIM models for all b-values clearly favouring
the inclusion of the pseudodiffusion/perfusion compo-
nent. The median residuals from fitting the ADC and
IVIM models for the whole kidney in the entire study
population, taken as a proxy for quality of model fitting
and normalised to degrees of freedom, were 24.3 and
12.3 a.u., respectively.
Taking the diffusion parameter D from the IVIM
model, and comparing to the perfusion-insensitive ADC
(calculated using b = 200 mm−2s and higher), an ex-
pected good agreement was found both at baseline and
following drug challenge (Tables 1 and 2). Pearson cor-
relation coefficients for whole kidney ROIs from all
studies were 0.86 at baseline and 0.98 post-challenge.
Repeatability
Good measurement repeatability of both diffusion and
BOLD parameters was determined. The percentage
change in fitted T2* in the ROI from baseline re-
vealed no significant deviation, less than 2.6 %, over
the experimental timecourse (CoVs from each time
point to the next were less than 1 %), and was small
relative to the effects determined following drug chal-
lenges (Fig. 3, Table 3). Diffusion characteristics also
showed no substantive change, except for D, which
showed a significant decrease (p < 0.05) for the whole
kidney ROI, although this result was not mirrored in
the ADC fitting, which showed no significant change
(Table 1). CoVs were comparable for ADC and D in
each of the ROIs considered, indicating the robust-
ness of fitting true diffusion, with the fast pseudo-
diffusion constant D* from the IVIM model having a
substantially higher CoV.
Fig. 2 Representative diffusion signal plots. Signal intensity (arbitrary units) plotted against diffusion b-value for a single voxel acquired from one
rat kidney, showing the fitted bi-exponential IVIM model (black line), favoured in the presence of a perfusion contribution, and single exponential
ADC model (grey line)
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Hydralazine
Hydralazine induced significant changes in all the dif-
fusion parameters (p < 0.05) for all regions, except the
medulla vascular fraction (f ) among the fitted IVIM
diffusion parameters (Table 2). Ladder plots of me-
dian results for individual whole-kidney ROIs showed
remarkable consistency, with f, D*, and fD* increas-
ing, and D decreasing (Fig. 4; perfusion-insensitive
ADC closely matched D for response). For the cortex
and medulla ROIs the same trend was observed, with
the cortex having higher f and lower ADC than the
medulla. The highly vascular renal cortex appeared to
account for the majority of the increase in f observed
at the whole-kidney level. BOLD MRI showed a
progressive decrease in T2* after administration of hy-
dralazine, becoming significant (p < 0.05) after 11 min
(Table 3). Representative T2* maps from a repeatability
scan (no intervention), together with maps acquired prior
to and post-hydralazine, are shown in Fig. 5, clearly
showing the pharmacologically-induced change in trans-
verse relaxation.
Furosemide
Diffusion parameter response to furosemide was more
wide-ranging than the response to hydralazine, with
greater variations between subjects (Fig. 4), but with no
significant change in vascular fraction overall. In con-
trast, the D and perfusion-insensitive ADC increased
significantly and consistently in all ROIs, but D* was
unaffected (Fig. 4). The temporal BOLD response post
administration was pronounced, with an immediate and
significant (p < 0.05) increase in T2* that reached over
125 % of baseline value at 6 min and remained elevated
for the final time point.
Angiotensin II
Infusion of angiotensin II induced marked inter-renal
variation in DWI response, with a significant (p < 0.05)
Table 1 Repeatability measurements for ADC and IVIM diffusion models
Kidney Cortex Medulla
Scan 1 Scan 2 CoV (%) Scan 1 Scan 2 CoV (%) Scan 1 Scan 2 CoV (%)
f (%) 26.9 ± 1.1 27.7 ± 2.3 18.7 27.1 ± 3.1 29.7 ± 3.7 24.5 23.4 ± 1.9 25.3 ± 3.5 22.5
D (10−5 mm2s−1) 124.5 ± 7.5 113.4 ± 4.4 6.2 105.0 ± 5.2 96.7 ± 6.9 12.4 133.0 ± 10.6 119.4 ± 7.3 7.4
ADC (10−5 mm2s−1) 101.9 ± 7 105.8 ± 4.4 9.3 85.5 ± 6.7 89.7 ± 7.3 17.5 111.3 ± 7.3 117.6 ± 5.5 11.9
D* (10−2 mm2s−1) 4.0 ± 0.4 5.4 ± 0.8 24.3 3.7 ± 0.5 4.5 ± 0.8 32.8 4.2 ± 0.5 5.6 ± 0.9 27.4
fD* (10−4 mm2s−1) 95.2 ± 7.3 151.2 ± 33.3 30.6 81.8 ± 6.8 129.5 ± 29.2 41.6 86.0 ± 9.0 150.4 ± 42.3 39.9
Table 2 Fitted ADC and IVIM parameter estimates following vasomodulator challenge
Kidney Cortex Medulla
Challenge pre post pre post pre post
Hydralazine 10.9 ± 0.7 15.1 ± 0.8a 17.4 ± 2.1 24.4 ± 2.6a 7.2 ± 0.8 8.3 ± 1.3
f Furosemide 12.0 ± 1.4 10.1 ± 1.0b 17.1 ± 1.0 12.0 ± 1.5a 9.6 ± 1.7 8.2 ± 1.3b
(%) Angiotensin II 19.3 ± 1.5 18.7 ± 1.6 23.9 ± 2.9 21.6 ± 2.1 15.3 ± 1.5 13.3 ± 1.3
Hydralazine 133.9 ± 5.9 100.2 ± 6.6a 130.3 ± 7.2 96.8 ± 8.8a 139.3 ± 4.0 109.6 ± 5.4a
D Furosemide 118.8 ± 5.8 138.8 ± 5.0a 117.5 ± 7.7 137.4 ± 7.9a 123.5 ± 5.4 141.6 ± 4.3a
(10−5 mm2s−1) Angiotensin II 118.8 ± 7.0 115.0 ± 4.4 116.4 ± 7.3 110.7 ± 4.7 129.1 ± 8.7 123.8 ± 5.7
Hydralazine 130 ± 6.0 97.9 ± 7.1a 126.6 ± 6.5 87.9 ± 8.9a 139.0 ± 4.0 111.8 ± 6.2a
ADC Furosemide 117.1 ± 5.8a 136.2 ± 5.7a 114.1 ± 9.1a 134.5 ± 8.6a 122.7 ± 5.5a 141.1 ± 5.6a
(10−5 mm2s−1) Angiotensin II 110.9 ± 7.7 110.9 ± 3.9 103.1 ± 8.1 102.2 ± 4.7 126.0 ± 8.8 122.2 ± 2.7
Termination 91.3 ± 9.5 68.0 ± 4.3a 84.1 ± 9.8 60.5 ± 5.3a 100.7 ± 10.2 79.0 ± 10.7
Hydralazine 4.0 ± 0.2 5.0 ± 0.2a 3.3 ± 0.4 5.0 ± 0.2a 4.3 ± 0.3 4.9 ± 0.2a
D* Furosemide 3.6 ± 0.2 3.8 ± 0.1 3.2 ± 0.3 3.7 ± 0.2 3.8 ± 0.2 3.6 ± 0.2
(10−2 mm2s−1) Angiotensin II 4.3 ± 0.5 5.1 ± 0.3 4.2 ± 0.4 4.5 ± 0.3 4.3 ± 0.6 5.2 ± 0.4b
Hydralazine 38.7 ± 1.7 65.6 ± 1.9a 48.1 ± 3.4 96.7 ± 9.2a 25.2 ± 0.9 35.6 ± 3.7a
fD* Furosemide 38.4 ± 5.0 32.5 ± 3.2 48.4 ± 5.0 37.8 ± 4.3a 29.9 ± 4.7 25.0 ± 2.7
(10−4 mm2s−1) Angiotensin II 71.2 ± 11.5 80.8 ± 10.8 76.8 ± 9.4 83.0 ± 12.9 59.0 ± 12.3 62.8 ± 9.5
Data are reported as mean of median ROI values ± standard error
aindicates p < 0.05 against baseline
bindicates p < 0.1 against baseline
Jerome et al. BMC Nephrology  (2016) 17:142 Page 5 of 9
increase determined in medulla D* only (Fig. 4). This
was associated with a significant (p < 0.05 for baseline
against post-administration time points) yet potentially
transient decrease in T2*.
Discussion
In this study, we developed and applied a multi-
parametric MRI strategy to evaluate the combination of
DW and BOLD MRI for the assessment of rat renal
function in vivo on a 1.5T clinical platform. IVIM DWI
allows for the estimation of a fast component of water
diffusivity (f, D*, and fD*) related to renal perfusion and
tubular excretion, in addition to measuring tissue diffu-
sivity (D). A challenge of using IVIM DWI to measure
renal function is the difficulty in decoupling vascular
and tubular contributions, as the two are intimately
linked through autoregulation to maintain homeostasis.
Additional mechanistic insight may be possible by com-
bining IVIM DWI data with quantitative T2* measure-
ments using BOLD MRI, which reflects renal blood
volume and tissue oxygenation. Studies have shown that
increased T2* in the kidneys can result from increased
hypoxia from higher tubular metabolism or increased
blood volume [23, 24]. Combining IVIM DWI with T2*
measurements allows corroboration of mutual informa-
tion to explain changes in renal physiology with pharma-
cological/physiological intervention.
Repeatability measurements are critical for providing
confidence in observed changes following experimental
intervention, but are not routinely performed in pre-
clinical imaging investigations. In this study, we first
established the repeatability of the quantitative MRI
biomarkers, with low CoVs for repeated measures dem-
onstrating that the functional parameters did not suffer
from instability over the imaging timecourse. Compari-
son of the perfusion-insensitive ADC and the IVIM par-
ameter D showed good agreement both prior to and
during challenge, suggesting that perfusion effects are
mostly removed at b-values >200 mm−2s. Although the
validity of this assumption will vary with different tis-
sues, this demonstrates the usefulness of the Bayesian
fitting method used herein for removing this assumption
and fitting the whole dataset, rather than the more com-
mon two-stage fitting of IVIM data. The use of clinical
vendor surface coils used in parallel with volume coils
provided sufficient signal and resolution to measure the
MRI biomarkers with good repeatability. Unsurprisingly,
measurement repeatability was poorer for the perfusion
sensitive parameters compared with the perfusion-
insensitive parameters and T2*.
We then proceeded to evaluate the effects of drugs
known to modulate renal vascular and tubular function.
Hydralazine is a well-characterised systemic vasodilator
that relaxes vascular smooth muscle; the increased
Fig. 3 Timecourse of intrinsic susceptibility contrast measurements. Graphs showing percentage change in renal T2* following administration of
saline or vasomodulators. Data points are mean ± 1 standard error of median ROI values
Table 3 Renal T2* (ms) for successive timepoints following
challenge
Time 0 2m15s 6m51s 11m24s
Repeatability 32.8 ± 1.4 33.3 ± 1.5 33.7 ± 1.5a 33.5 ± 1.3
Hydralazine 37.7 ± 2.0 36.7 ± 2.3 34.5 ± 1.5 30.2 ± 1.4a
Furosemide 38.5 ± 2.2 44.7 ± 2.4ab 48.5 ± 2.8ab 47.8 ± 3.0a
Angiotensin II 34.5 ± 2.4 29.8 ± 1.9ab 29.4 ± 1.1a 30.7 ± 1.1a
Data are reported as mean of median ROI values ± 1 standard error of
the mean
aindicates p < 0.05 against baseline
bindicates p < 0.05 against previous timepoint
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vascular fraction determined in the IVIM model, and re-
duction in T2*, is consistent with a hydralazine-induced
increase in (deoxygenated) renal blood volume. Further-
more, the associated reduction in blood flow induces a
compensatory increase in cardiac output to maintain
blood pressure [25], resulting in the observed increase in
D* with net increased blood flow. To maintain fluid
homeostasis, the kidney may also increase tubular trans-
port, the resulting increase in oxygen consumption also
contributing to the reduction in T2*. The decrease in the
perfusion-insensitive ADC and D can be interpreted as a
consequence of dehydration of the interstitial space.
Furosemide is a loop diuretic, inhibiting water reabsorp-
tion in the nephron by blocking the sodium-potassium-
chloride co-transporter in the ascending limb of the loop
of Henlé. The rapid and significant increase in T2* seen
herein is consistent with previous reports and the known
effects of furosemide on reducing renal blood volume and
decreasing oxygen consumption [14, 26, 27]. A reduction
in perfusion fraction in the renal cortex was also
observed, suggesting a reactive decrease in vascular
flow, and also consistent with a reduction in blood
volume. Interestingly, the perfusion-insensitive ADC
Fig. 4 Sensitivity of diffusion-weighted imaging parameters. Individual ladder plots (grey) and cohort means (black) for diffusion parameters
derived from whole kidney ROIs, determined prior to and following administration of hydralazine, furosemide or angiotensin II
Fig. 5 Repeatability measurements show parameter stability.
Functional T2* maps (overlaid on TE = 5 ms image) for whole kidney
(a) with no intervention showing measurement repeatability, and b)
prior to and 11 min following intravenous administration
of hydralazine
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and D significantly increased, consistent with an in-
crease in renal water content within the tubules due
to diuretic effects. This contrasts with previous stud-
ies showing either no change, or a reduction in renal
water diffusivity, in response to furosemide [14, 28].
Angiotensin II is a naturally-occurring hormone with a
complex role within the renal renin-angiotensin system
(RAS) [29]. The hormone has a direct effect on the
proximal tubules to increase Na+ reabsorption, and has
a convoluted and variable effect on glomerular filtration
and renal blood flow. Increases in systemic blood pres-
sure will maintain renal perfusion pressure; however,
constriction of the afferent and efferent glomerular arte-
rioles can reduce renal blood flow. The effect on the ef-
ferent arteriolar resistance tends to increase glomerular
capillary hydrostatic pressure and maintain glomerular
filtration rate. In the present study, the initial reduction
in T2* is consistent with an acute reduction in blood vol-
ume and tissue oxygenation, the suggestion of a recovery
towards baseline may reflect a reactive response to drug-
induced vasoconstriction. A similar transient T2* re-
sponse to angiotensin II has been reported in human
kidney [30]. The DWI data revealed no significant
changes, which supports the concept of an acute effect-
ive homeostatic response, and the absence of any vascu-
lar response in the IVIM parameters.
Animal welfare and ways of reducing animal usage is
an important consideration for all research bioscientists;
non-invasive and longitudinal imaging methods that in-
corporate repeatability measurements can reduce the
number of animals by using each as its own control, har-
nessing statistical power through the use of paired statis-
tical tests in small animal cohorts, and information that
may relate better to that observed in clinical assessment
of therapy efficacy. Clinical MRI scanners are being
increasingly used for pre-clinical imaging studies. Com-
pared to relatively expensive dedicated small-bore ani-
mal MRI systems, major vendors sell and distribute far
more clinical scanners; consequences of this include the
continuing development and availability of superior
hardware and standardised pulse sequences on these
platforms. Pre-clinical studies performed on clinical plat-
forms also provide evidence supporting the clinical rele-
vance of advanced diffusion modelling and data
acquisition. Most clinical scanners operate at between
1.5 and 3 Tesla, and thus have lower signal-to-noise
(SNR) levels than pre-clinical systems, with reduced
image quality if conventional clinical imaging coils are
used. This is exacerbated particularly when imaging the
small fields-of-view necessary when using rodents, but
with a high enough resolution to be able to acquire
meaningful functional data. One approach for increasing
SNR is to use small, dedicated receiver coils, such as the
TMJ coil used herein, designed to fit closely to the
object of interest, giving a better coupling between the
object and coil with a corresponding increase in signal
and thus improved image quality [31]. Here we have
shown the sensitivity and stability of parallel imaging
using standard vendor coils on a clinical 1.5T MR system
for conducting rodent renal studies, and demonstrate the
sensitivity of resulting DWI and BOLD MRI biomarkers
to the effects of several vasomodulators. This experimen-
tal arrangement extends the available scope for perform-
ing pre-clinical studies with existing clinical hardware, and
confers the advantages associated with increased access to
clinical scanners for pre-clinical studies.
Some limitations in this study are clear. Firstly, due to
the voxel size achievable on clinical 1.5T MR systems,
we were limited in our ability to reliably draw smaller
ROIs to interrogate regions within the kidney that may
contain differential vascular/tubular components, and
this was particularly true for DWI where signal is ac-
tively attenuated by the sensitising gradients. Hence,
analysis was necessarily made over larger regions to en-
sure adequate image SNR. Secondly, the dynamic im-
aging protocol precluded the use of other complex
invasive measurements to provide additional validation
of our observations against other physiological measures
over the experimental period.
Conclusions
We have shown that IVIM DWI and T2* measurements are
feasible on a 1.5T clinical MR system to monitor the acute
effects of vascular and tubular modulating drugs on rat kid-
ney function in vivo. Water diffusion in kidneys exhibits bi-
exponential behaviour, with the fast diffusion component at
low b-values reflecting both vascular and tubular flow.
Multi-parametric MRI strategies combining IVIM DWI
with T2* measurements allows mutual corroboration of
pharmacological interventions. The administration of intra-
venous hydralazine, furosemide, or angiotensin showed dif-
ferential effects on IVIM DWI and BOLD MRI biomarkers
in vivo, and highlights the potential of these techniques to
study the effects of drugs that modulate renal function in
humans, so as to better understand their treatment effects
in patients with renal dysfunction.
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